AstraZeneca reports positive results from extension of DURATION-1 trial of Bydureon

AstraZeneca has reported positive results from the extension of the DURATION-1 trial of exenatide for treatment of patients with type 2 diabetes.

Source: Drug Development Technology - June 16, 2014 Category: Pharmaceuticals Source Type: news